Jones Microbiology Institute
Jones Microbiology Institute is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options
Sponsor Mundipharma Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Sponsor Elion Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)
Sponsor Mundipharma Research Limited
- Start (EU)
- Latest update
- Estimated end
A Multi-Center, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vabomere (meropenem-vaborbactam) in the Treatment of Children with Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Sponsor Rempex Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole (MARIO)
Sponsor Scynexis Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously (IV) administered imipenem-cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)
Sponsor Spero Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (OPERA-T study)
Sponsor Pulmocide Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Jones Microbiology Institute?
The 2026-10-09 snapshot links Jones Microbiology Institute to 7 distinct CTIS trials. Recorded services include Laboratory services, Fungal isolate long-term storage, microbiology isolates analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Jones Microbiology Institute?
The most frequently recorded therapeutic areas are Infectious Disease, Respiratory. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Jones Microbiology Institute conducted?
The linked trials record locations in 16 countries, including Belgium, Spain, France, Italy, Germany. These are trial locations, not confirmed office locations or countries where Jones Microbiology Institute delivered services.
What can this page tell me about Jones Microbiology Institute's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Jones Microbiology Institute. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Jones Microbiology Institute Inc.